

Status (Multiple Items)

| Drug Name      | Tumour Group     | Regimen Name on NCCP website   | Regimen Number |
|----------------|------------------|--|----------------|
| 5-Fluorouracil | Breast           | 5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy                  | 265            |
|                |                  | 5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy                     | 269            |
|                |                  | Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy              | 381            |
|                |                  | Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy              | 378            |
|                |                  | Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy                   | 377            |
|                | Gastrointestinal | 5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy                            | 451            |
|                |                  | 5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day            | 421            |
|                |                  | Aflibercept-14 days  | 238            |
|                |                  | Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day                                | 446            |
|                |                  | Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days                                       | 449            |
|                |                  | CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen          | 460            |
|                |                  | epiRUBicin, CISplatin and 5-FU (ECF) Therapy   | 240            |
|                |                  | epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day                                 | 429            |
|                |                  | FLOT Therapy-14 day  | 344            |
|                |                  | FLOX Therapy   | 486            |
|                |                  | FOLFIRI (14 days)+ Cetuximab (14 days) Therapy   | 585            |
|                |                  | FOLFIRI (14 days)+ Cetuximab (7 days) Therapy  | 328            |
|                |                  | FOLFIRI Therapy-14 day   | 227            |
|                |                  | FOLFIRINOX Therapy   | 329            |
|                |                  | FOLFOX-4 Therapy-14 day  | 210            |
|                |                  | FOLFOXIRI Therapy  | 555            |
|                |                  | Modified FOLFIRINOX Therapy  | 515            |
|                |                  | Modified FOLFOX-6 Chemoradiation Therapy-14 day  | 509            |
|                |                  | Modified FOLFOX-6 Therapy-14 day   | 209            |
|                |                  | Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day  | 448            |
|                |                  | Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day                              | 447            |
|                |                  | QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly                | 428            |
|                |                  | Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days                             | 502            |
|                |                  | CISplatin, Infusional 5-Fluorouracil and Radiation Therapy                             | 594            |
|                |                  | Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen | 427            |
|                |                  | 5-Fluorouracil and Folinic Acid Therapy-14 day   | 660            |
|                |                  | FOLFIRINOX Therapy - (Rectal Carcinoma)  | 691            |
|                |                  | Cetuximab and FOLFOX-4 Therapy   | 692            |
|                |                  | Trastuzumab and FOLFOX-6 Modified Therapy-14 day                                       | 704            |
|                |                  | Cetuximab and FOLFOX-6 (modified) Therapy  | 733            |
|                |                  | Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days                                      | 783            |
|                |                  | Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy           | 739            |

|                  |                  |  |   |               |   |     |
|------------------|------------------|--|---|---------------|---|-----|
| 5-Fluorouracil   | Gastrointestinal | Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy | 816   |               |   |     |
|                  |                  | Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy | 832   |               |   |     |
|                  |                  | Pembrolizumab and FOLFOX-6 Modified Therapy                              | 839   |               |   |     |
|                  |                  | Nivolumab and FOLFOX-6 Modified Therapy                                  | 844   |               |   |     |
|                  |                  | 5-Fluorouracil and mitoMYcin Chemoradiation Therapy                      | 450   |               |   |     |
|                  | Head & Neck      | Genitourinary  | CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle         | 552           |   |     |
|                  |                  |  | Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle | 418           |   |     |
|                  |                  |  | Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle | 417           |   |     |
|                  |                  |  | CISplatin and 5-Fluorouracil Therapy-28 day   | 314           |   |     |
|                  |                  |  | DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy                               | 324           |   |     |
|                  |                  |  | DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy          | 323           |   |     |
|                  |                  |  | Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery     | 315           |   |     |
|                  |                  |  | CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy                   | 589           |   |     |
|                  |                  |  | CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy                     | 591           |   |     |
|                  |                  |  | Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy                       | 705           |   |     |
|                  |                  |  | Pembrolizumab, CISplatin and 5-Fluorouracil Therapy                                 | 706           |   |     |
|                  |                  |  | Abiraterone   | Genitourinary | Abiraterone 1000mg and Prednisolone 5mg Therapy | 577 |
|                  |                  |  |   |               | Abiraterone and Prednisolone Therapy            | 103 |
|                  |                  |  | Acalabrutinib   | Leukaemia     | Acalabrutinib (Tablets) Monotherapy             | 840 |
| Afatinib         | Lung             | Afatinib Monotherapy   | 221   |               |   |     |
| Aflibercept      | Gastrointestinal | Aflibercept-14 days  | 238   |               |   |     |
| Alectinib        | Lung             | Alectinib Monotherapy  | 401   |               |   |     |
| Alemtuzumab      | Transplant       | Fludarabine/Melphalan/Alemtuzumab-RIC-SIB                                | 611   |               |   |     |
|                  |                  | Fludarabine/Melphalan/Alemtuzumab-RIC-MUD                                | 625   |               |   |     |
|                  |                  | Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD        | 638   |               |   |     |
| Anastrozole      | Breast           | Anastrozole Monotherapy  | 254   |               |   |     |
| Apalutamide      | Genitourinary    | Apalutamide therapy  | 574   |               |   |     |
| Arsenic trioxide | Leukaemia/BMT    | Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy       | 357   |               |   |     |
|                  |                  | Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy           | 356   |               |   |     |
| Asciminib        | Leukaemia        | Asciminib Monotherapy  | 847   |               |   |     |
| Atezolizumab     | Breast           | Atezolizumab and nab-PACLitaxel Therapy                                  | 688   |               |   |     |
|                  |                  | Genitourinary  | Atezolizumab 1200mg Monotherapy   | 544           |   |     |
|                  |                  | Atezolizumab 1680mg Monotherapy – 28 Day                                 | 593   |               |   |     |
|                  |                  | Atezolizumab Monotherapy-14 day  | 592   |               |   |     |
|                  | Lung             | Atezolizumab 1200mg Monotherapy  | 544   |               |   |     |
|                  |                  | Atezolizumab 1680mg Monotherapy – 28 Day                                 | 593   |               |   |     |
|                  |                  | Atezolizumab Monotherapy-14 day  | 592   |               |   |     |
|                  |                  | Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy    | 689   |               |   |     |
| Avelumab         | Skin/Melanoma    | Avelumab Monotherapy   | 535   |               |   |     |

|                      |                  |  |     |
|----------------------|------------------|--|-----|
| Axicabtagene ciloleu | Lymphoma (CAR-T) | Axicabtagene ciloleu (Yescarta®) (CAR-T) DLBCL and PMBCL   | 717 |
| Axitinib             | Genitourinary    | Axitinib Monotherapy   | 104 |
|                      |                  | Pembrolizumab 200mg and Axitinib Therapy   | 583 |
| Azacitidine          | Leukaemia/BMT    | Azacitidine 100mg/m <sup>2</sup> 5-day Therapy   | 288 |
|                      |                  | Azacitidine 75mg/m <sup>2</sup> 5-2-2 Therapy  | 287 |
| Azacitidine          | Leukaemia        | azaCITIDine (Oral) Monotherapy   | 818 |
| Bendamustine         | Leukaemia/BMT    | Bendamustine Monotherapy   | 527 |
|                      | Lymphoma         | Brentuximab vedotin and Bendamustine Therapy   | 529 |
|                      |                  | Obinutuzumab and Bendamustine Therapy-28 day cycle   | 424 |
|                      |                  | riTUXimab and Bendamustine Therapy   | 345 |
|                      |                  | Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy  | 685 |
| Bevacizumab          | Breast           | Bevacizumab 10mg/kg-14days   | 212 |
|                      |                  | Bevacizumab 15mg/kg - 21 days  | 215 |
|                      |                  | Bevacizumab 10mg/kg and PACLitaxel 80mg/m <sup>2</sup> Therapy                                     | 738 |
|                      | Gastrointestinal | Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day  | 446 |
|                      |                  | Bevacizumab 10mg/kg-14days   | 212 |
|                      |                  | Bevacizumab 15mg/kg - 21 days  | 215 |
|                      |                  | Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days   | 449 |
|                      |                  | Bevacizumab 7.5mg/kg-21days  | 214 |
|                      |                  | Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m <sup>2</sup> Therapy - 21 day                       |     |
|                      |                  | Therapy- 21 day  | 623 |
|                      |                  | Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days  | 783 |
|                      |                  | Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m <sup>2</sup> Therapy - 21 day                       | 623 |
|                      | Genitourinary    | Bevacizumab 10mg/kg-14days   | 212 |
|                      | Gynaecology      | Bevacizumab 10mg/kg-14days   | 212 |
|                      |                  | Bevacizumab 15mg/kg - 21 days  | 215 |
|                      |                  | Gemcitabine (1000mg/m <sup>2</sup> ), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day | 499 |
|                      |                  | Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m <sup>2</sup> Therapy               | 620 |
|                      |                  | Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m <sup>2</sup>                         | 716 |
|                      |                  | Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m <sup>2</sup> Therapy               | 766 |
|                      |                  | Bevacizumab 10mg/kg and PACLitaxel 80mg/m <sup>2</sup> (day 1,8,15,22) Therapy                     | 769 |
|                      |                  | Bevacizumab 10mg/kg and Topotecan 4mg/m <sup>2</sup> therapy                                       | 771 |
|                      |                  | Bevacizumab 15mg/kg, PACLitaxel 175mg/m <sup>2</sup> and CISplatin 50mg/m <sup>2</sup> Therapy     | 799 |
|                      |                  | Pembrolizumab, PACLitaxel 175mg/m <sup>2</sup> , CARBOplatin AUC 5 and Bevacizumab Therapy         | 811 |
|                      |                  | Olaparib (Tablet) and Bevacizumab Therapy  | 746 |
|                      |                  | Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m <sup>2</sup> therapy                          | 772 |
|                      | Lung             | Bevacizumab 15mg/kg - 21 days  | 215 |
|                      |                  | Bevacizumab 7.5mg/kg-21days  | 214 |
|                      | Neuro-oncology   | Lomustine and Bevacizumab 5mg/kg Therapy   | 742 |

|  |                                 |  |  |
|--|---------------------------------|--|--|
| Bevacizumab  | Neuro-oncology                  | Lomustine and Bevacizumab 7.5mg/kg Therapy   | 804  |
|  |                                 | Bevacizumab 5mg/kg Monotherapy – 14 Day  | 813  |
| Bicalutamide   | Genitourinary                   | Bicalutamide Therapy   | 482  |
| binimetinib  | Skin/Melanoma                   | Encorafenib and Binimetinib Therapy  | 563  |
| Bleomycin  | Lymphoma                        | ABVD Therapy   | 290  |
|  |                                 | Escalated Dose BEACOPP 21 day Therapy  | 354  |
|  | Genitourinary/Gyn               | Bleomycin, Etoposide and CISplatin (BEP)Therapy                                      | 300  |
| Blinatumomab   | Leukaemia/BMT                   | Blinatumomab Therapy   | 538  |
|  |                                 | Blinatumomab Therapy (ALL with MRD>0.1%  | 590  |
|  | Paediatric Oncology             | Blinatumomab Paediatric Therapy  | P00567                                       |
| Bortezomib   | Myeloma                         | Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy                      | P00707                                       |
|  |                                 | Bortezomib , Melphalan and Prednisolone  | 275  |
|  |                                 | Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy                       | 274  |
|  |                                 | Bortezomib and Dexamethasone Therapy   | 270  |
|  |                                 | Bortezomib Maintenance Therapy- 14 day   | 435  |
|  |                                 | Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day                     | 416  |
|  |                                 | Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy       | 299  |
|  |                                 | Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy               | 273  |
|  |                                 | Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy                             | 601  |
|  |                                 | Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day                    | 643  |
|  |                                 | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy        | 703  |
|  |                                 |  | 752  |
|  |                                 | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy    | 755  |
|  |                                 |  | 756  |
|  |                                 | Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy               | 780  |
| Bortezomib and Lenalidomide RVD lite consolidation therapy | 781                             |  |  |
| Bortezomib   | Myeloma                         | Daratumumab (IV), bortezomib and dexamethasone therapy                               | 560  |
|  |                                 | Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy                        | 609  |
|  |                                 | Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy               | 695  |
| Bosutinib  | Leukaemia/BMT                   | Bosutinib Monotherapy  | 224  |
| Brentuximab vedotin  | Leukaemia/BMT                   | Brentuximab vedotin Monotherapy  | 234  |
|  |                                 | Lymphoma   | Brentuximab vedotin and Bendamustine Therapy |
|  | Lymphoma                        | Brentuximab vedotin and ESHAP therapyi (BRESHAP)                                     | 530  |
|  |                                 | Brentuximab vedotin Monotherapy  | 234  |
|  |                                 | Brentuximab vedotin and ICE Therapy  | 528  |
|  |                                 | Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) Therapy | 801  |
| Lymphoma   | Brentuximab vedotin Monotherapy | 234  |  |
| Brigatinib   | Lung                            | Brigatinib Therapy   | 562  |

|              |                  |   |     |
|--------------|------------------|---|-----|
| Busulfan     | Transplant       | Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD  | 635 |
|              |                  | Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB   | 636 |
|              |                  | Busulfan/Cyclophosphamide MAC-MUD   | 639 |
|              |                  | Busulfan/Cyclophosphamide MAC-SIB   | 641 |
|              |                  | Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor   | 662 |
|              |                  | Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor   | 663 |
| Cabazitaxel  | Genitourinary    | Cabazitaxel and Prednisolone  | 101 |
| Cabozantinib | Genitourinary    | Cabozantinib Therapy  | 518 |
| Capecitabine | Breast           | Capecitabine Monotherapy  | 216 |
|              |                  | Lapatinib and Capecitabine  | 217 |
|              | Gastrointestinal | Capecitabine 825mg/m2 and RT–7 day  | 586 |
|              |                  | Capecitabine and RT – 7 day   | 523 |
|              |                  | Capecitabine and Temozolomide Therapy*  | 505 |
|              |                  | Capecitabine Monotherapy  | 216 |
|              |                  | Capecitabine/Oxaliplatin (XELOX) Therapy  | 321 |
|              |                  | CISplatin and Capecitabine Adjuvant Chemoradiation Therapy  | 473 |
|              |                  | epiRUBicin, CISplatin and Capecitabine (ECX) Therapy  | 380 |
|              |                  | epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy  | 239 |
|              |                  | Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days   | 524 |
|              |                  | Gemcitabine + Capecitabine Therapy  | 384 |
|              |                  | Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day  | 623 |
|              |                  | Therapy- 21 day   | 623 |
|              |                  | FOLFIRINOX Therapy - (Rectal Carcinoma)   | 691 |
|              |                  | mitoMYcin and Capecitabine Chemoradiation Therapy   | 727 |
|              |                  | Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day  | 623 |
| CARBOplatin  | Breast           | CARBOplatin (AUC4-6) Monotherapy-21 days  | 261 |
|              |                  | CARBOplatin (AUC4-6) Monotherapy-28 days  | 251 |
|              |                  | CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy  | 348 |
|              |                  | DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days  | 258 |
|              |                  | Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days  | 430 |
|              |                  | DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy   | 722 |
|              |                  | DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy  | 731 |
|              |                  | Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)   | 775 |
|              |                  | DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy   | 789 |
|              |                  | Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)  | 790 |
|              |                  | Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy | 734 |

|             |   |   |   |     |
|-------------|---|---|---|-----|
| CARBOplatin | Gastrointestinal  | CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks                        | 422   |     |
|             | Genitourinary   | CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen                                | 453   |     |
|             |   | Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day   | 310   |     |
|             |   | TICE -Autologous Conditioning Germ Cell Tumour Regimen  | 437   |     |
|             | Gynaecology   | CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)   | 419   |     |
|             |   | CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy   | 308   |     |
|             |   | CARBOplatin (AUC4-6) Monotherapy-21 days  | 261   |     |
|             |   | CARBOplatin (AUC4-6) Monotherapy-28 days  | 251   |     |
|             |   | CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy  | 303   |     |
|             |   | Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day   | 306   |     |
|             |   | Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day                             | 499   |     |
|             |   | Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy  | 620   |     |
|             |   | Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day                                      | 624   |     |
|             |   | CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer | 676   |     |
|             |   | Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2  | 716   |     |
|             |   | Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy  | 766   |     |
|             |   | Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy                                     | 811   |     |
|             |   | Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy  | 817   |     |
|             |   | Head & Neck   | CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)                                   | 419 |
|             |   |   | CARBOplatin (AUC4-6) Monotherapy-21 days  | 261 |
|             |   |   | CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days                                 | 332 |
|             |   |   | CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle         | 552 |
|             |   |   | Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle | 418 |
|             | CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy |   | 589   |     |
|             | CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy   |   | 591   |     |
|             | Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy     |   | 705   |     |
|             | Lung  |   | CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day    | 561 |
|             |   |   | CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day                            | 271 |
|             |   | CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy  | 304   |     |
|             |   | CARBOplatin and Oral Etoposide Therapy-21 days  | 319   |     |
|             |   | Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day   | 310   |     |
|             |   | Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy   | 579   |     |
|             |   | Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy   | 568   |     |

|                   |                  |  |     |
|-------------------|------------------|--|-----|
| CARBOplatin       | Lung             | PEMEtrexed and CARBOplatin Therapy   | 318 |
|                   |                  | Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m <sup>2</sup> Therapy   | 309 |
|                   |                  | CARBOplatin and vinORELbine Therapy-21 Day   | 614 |
|                   |                  | Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m <sup>2</sup> Therapy                            | 689 |
|                   |                  | Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy  | 712 |
|                   |                  | Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy  | 713 |
|                   |                  | (R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy                                       | 397 |
|                   | Lymphoma         | Brentuximab vedotin and ICE Therapy  | 528 |
|                   |                  | ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy  | 842 |
|                   |                  | (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient                          | 751 |
| Carfilzomib       | Myeloma          | Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day          | 598 |
|                   |                  | Carfilzomib (20/70mg/m <sup>2</sup> Once weekly) Dexamethasone (Kd) therapy - 28 day                         | 595 |
|                   |                  | Carfilzomib and Dexamethasone (Kd) Therapy - 28 day  | 566 |
| carfilzomib       | Myeloma          | Carfilzomib (27mg/m <sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day        | 405 |
|                   |                  | Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD  | 638 |
| Carmustine        | Transplant       |  |     |
| Carmustine (BCNU) | Lymphoma         | BEAM Autologous Transplant Conditioning Protocol   | 408 |
| Cemiplimab        | Gynaecology      | Cemiplimab Therapy   | 812 |
|                   | Skin/Melanoma    | Cemiplimab Therapy   | 812 |
| Ceritinib         | Lung             | Ceritinib Monotherapy  | 340 |
| Cetuximab         | Gastrointestinal | Cetuximab (14 days) and Irinotecan (14 days) Therapy   | 331 |
|                   |                  | Cetuximab (7 days) and Irinotecan (14 days) Therapy  | 330 |
|                   |                  | Cetuximab Monotherapy-7 days   | 207 |
|                   |                  | FOLFIRI (14 days)+ Cetuximab (14 days) Therapy   | 585 |
|                   |                  | FOLFIRI (14 days)+ Cetuximab (7 days) Therapy  | 328 |
|                   |                  | Cetuximab and FOLFOX-4 Therapy   | 692 |
|                   |                  | Cetuximab Therapy-14 days  | 732 |
|                   |                  | Cetuximab and FOLFOX-6 (modified) Therapy  | 733 |
|                   | Head & Neck      | Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m <sup>2</sup> /day Therapy - 21 day cycle             | 418 |
|                   |                  | Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle | 417 |
|                   |                  | Cetuximab Monotherapy-7 days   | 207 |
|                   |                  | Chlorambucil10mg/m <sup>2</sup> Therapy  | 411 |
|                   |                  | Obinutuzumab and Chlorambucil Therapy  | 286 |
| Chlorambucil      | Lymphoma         | Chlorambucil10mg/m <sup>2</sup> Therapy  | 411 |
| CISplatin         | Gastrointestinal | CISplatin 75mg/m <sup>2</sup> and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen                    | 460 |
|                   |                  | CISplatin and Capecitabine Adjuvant Chemoradiation Therapy   | 473 |
|                   |                  | CISplatin and Teysuno-28 day cycle   | 235 |
|                   |                  | epiRUBicin, CISplatin and 5-FU (ECF) Therapy   | 240 |
|                   |                  | epiRUBicin, CISplatin and Capecitabine (ECX) Therapy   | 380 |
|                   |                  | Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) Therapy- 21 day                    | 383 |
|                   |                  | Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days   | 502 |
|                   |                  | CISplatin, Infusional 5-Fluorouracil and Radiation Therapy   | 594 |



|           |   |   |  |     |
|-----------|---|---|--|-----|
| CISplatin | Gastrointestinal  | Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy      | 739  |     |
|           |   | Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy          | 816  |     |
|           |   | Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy          | 832  |     |
|           | Genitourinary   | CISplatin (40mg/m2) Weekly with Radiotherapy (RT)                                 | 385  |     |
|           |   | CISplatin, Methotrexate and Vinblastine Therapy                                   | 337  |     |
|           |   | Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day                   | 282  |     |
|           |   | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy | 333  |     |
|           |   | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days         | 338  |     |
|           |   | Gemcitabine (1000mg/m2 ) and CISplatin (35mg/m2 ) Therapy- 21 day                 | 622  |     |
|           |   | Gemcitabine (1000mg/m2 ) and CISplatin (70mg/m2 ) Therapy- 21 day                 | 628  |     |
|           |   | Gynaecology   | CISplatin (40mg/m2) Weekly with Radiotherapy (RT)                                    | 385 |
|           |   |   | PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy           | 266 |
|           |   |   | Two Day Etoposide CISplatin (EP) Therapy   | 267 |
|           | Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy   |   | 264  |     |
|           | CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer |   | 676  |     |
|           | Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy  |   | 799  |     |
|           | CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day   |   | 279  |     |
|           | Head & Neck   |   | Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle | 417 |
|           |   |   | CISplatin (100mg/m2) with Radiotherapy (RT)  | 387 |
|           |   |   | CISplatin (40mg/m2) Weekly with Radiotherapy (RT)                                    | 385 |
|           |   | CISplatin and 5-Fluorouracil Therapy-28 day                                       | 314  |     |
|           |   | DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy                             | 324  |     |
|           |   | DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy        | 323  |     |
|           |   | Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day                  | 517  |     |
|           |   | Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery   | 315  |     |
|           |   | Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day                      | 615  |     |
|           |   | Pembrolizumab, CISplatin and 5-Fluorouracil Therapy                               | 706  |     |
|           | Lung  | CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day  | 456  |     |
|           |   | CISplatin (75mg/m2) + Etoposide Therapy-21 day                                    | 280  |     |
|           |   | Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day                   | 281  |     |
|           |   | Pembrolizumab, PEMEtrexed and CISplatin Therapy                                   | 569  |     |
|           |   | PEMEtrexed and CISplatin Therapy  | 317  |     |
|           |   | Vinorelbine and CISplatin Therapy-21 days   | 339  |     |
|           |   | Vinorelbine and CISplatin Therapy-28 days   | 343  |     |



|   |                   |  |     |
|---|-------------------|--|-----|
| CISplatin                                       | Lung              | CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day  | 279 |
|   |                   | Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy  | 714 |
|   | Sarcoma           | (MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy  | 463 |
|   |                   | DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle  | 420 |
|   | Neuro-oncology    | CISplatin, Lomustine and vinCRISTine (CLV) Therapy   | 806 |
|   | Lymphoma          | (R**)-DHAP Therapy   | 395 |
|   |                   | Brentuximab vedotin and ESHAP therapyi (BRESHAP)   | 530 |
|   |                   | (R*)- ESHAP Therapy  | 394 |
|   |                   | riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)  | 441 |
|   | Genitourinary/Gyn | ESHAP Therapy  | 838 |
| Bleomycin, Etoposide and CISplatin (BEP)Therapy |                   | 300  |     |
| Cladribine                                      | Leukaemia/BMT     | Etoposide and CISplatin 20mg/m2 (EP) Therapy   | 301 |
|   |                   | Cladribine 0.14mg/kg Day 1 to 5 Therapy  | 402 |
|   | Leukaemia/BMT, L  | Cladribine 0.14mg/kg Weekly Therapy  | 469 |
|   |                   | Cladribine 5 day and riTUXimab Therapy   | 531 |
| Cobimetinib                                     | Skin/Melanoma     | Cladribine Weekly and riTUXimab Therapy  | 534 |
| Crizotinib                                      | Lung              | Cobimetinib and Vemurafenib Therapy  | 373 |
| Cyclophosphamide                                | Breast            | Crizotinib Monotherapy   | 243 |
|   |                   | 5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy  | 265 |
|   |                   | 5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy   | 269 |
|   |                   | CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy | 348 |
|   |                   | Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy  | 381 |
|   |                   | Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy  | 378 |
|   |                   | DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day  | 250 |
|   |                   | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)                                  | 278 |
|   |                   | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)                                    | 485 |
|   |                   | Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)                 | 316 |
|   |                   | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)              | 433 |
|   |                   | DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day  | 252 |
|   |                   | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)   | 260 |
|   |                   | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)                         | 432 |
|   |                   | epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day   | 263 |
|   |                   | epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day   | 262 |

|                  |   |   |     |
|------------------|---|---|-----|
| Cyclophosphamide | Breast  | Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)            | 745 |
|                  |   | Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy | 734 |
|                  | Gynaecology   | EMA/CO Therapy  | 248 |
|                  | Head & Neck   | Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day  | 615 |
|                  | Leukaemia/BMT   | Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy   | 241 |
|                  | Sarcoma   | Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals                                    | 675 |
|                  |   |   | 747 |
|                  | Lymphoma  | (**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days   | 409 |
|                  |   | (*riTUXimab), Cyclophosphamide VinCRIStine and Prednisolone (*R)-CVP) Therapy– 21 days  | 293 |
|                  |   | (R*)-CHOP – 21 days   | 307 |
|                  |   | (R**)- miniCHOP Therapy – 21 days   | 436 |
|                  |   | CHOEP Therapy– 21 days  | 396 |
|                  |   | Dose Adjusted R-EPOCH Therapy   | 355 |
|                  |   | Escalated Dose BEACOPP 21 day Therapy   | 354 |
|                  |   | Nordic Therapy  | 393 |
|                  |   | Obinutuzumab and CHOP Therapy – 21 day  | 549 |
|                  |   | obinutuzumab and CVP therapy -21 days   | 550 |
|                  |   | R-CEOP Therapy – 21 days  | 510 |
|                  |   | R-CODOX-M Therapy (Patients greater than 65 years)  | 403 |
|                  |   | R-CODOX-M Therapy (Patients less than or equal to 65 years)   | 398 |
|                  |   | riTUXimab-HyperCVAD Therapy (MCL) – Part A  | 466 |
|                  |   | Cyclophosphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days   | 841 |
|                  |   | riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRIStine and Prednisolone (R-CHOP) Therapy– 21 Days  | 667 |
|                  |   | Dose Adjusted R (S/C)-EPOCH Therapy   | 672 |
|                  |   | (*riTUXimab)-Gemcitabine Cyclophosphamide vinCRIStine and PrednisoLONE (*R)-GCVP) Therapy–21 days   | 737 |
|                  |   | Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) Therapy  | 801 |
|                  | Myeloma   | Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy  | 299 |
|                  |   | Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy  | 273 |
|                  | Lymphoma and M  | Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation   | 438 |
|                  | Lymphoma, Myelc   | Cyclophosphamide 1500mg/m2 For Stem Cell Mobilisation   | 795 |
|                  | Lymphoma (CAR-T   | Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL  | 606 |
|                  |   | Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)  | 608 |
| Leukaemia (CAR-T | Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL | 607   |     |

|  |   |   |     |
|--|---|---|-----|
| Cyclophosphamide   | Transplant  | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor                  | 629 |
|  |   | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor                    | 630 |
|  |   | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD   | 631 |
|  |   | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB   | 637 |
|  |   | Busulfan/Cyclophosphamide MAC-MUD   | 639 |
|  |   | Busulfan/Cyclophosphamide MAC-SIB   | 641 |
|  |   | Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor                       | 662 |
|  |   | Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor                     | 663 |
| Cyclophosphamide - Oral  | Breast  | Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy                         | 377 |
|  | Leukaemia/BMT   | Fludarabine, Cyclophosphamide and ritUXimab (FC Oral+R) Therapy                               | 410 |
|  | Lymphoma  | Dexamethasone, ritUXimab and Cyclophosphamide (DRC)Therapy                                    | 532 |
| Cytarabine   | Leukaemia/BMT   | DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)   | 360 |
|  |   | DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)  | 359 |
|  |   | FLAG:Ida 8mg/m2 Therapy   | 362 |
|  |   | High Dose Cytarabine Therapy  | 365 |
|  |   | Intermediate Dose Cytarabine Therapy  | 364 |
|  |   | Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction) | 612 |
|  | Lymphoma  | (R**)-DHAP Therapy  | 395 |
|  |   | BEAM Autologous Transplant Conditioning Protocol  | 408 |
|  |   | Brentuximab vedotin and ESHAP therapy (BRESHAP)   | 530 |
|  |   | High dose Methotrexate, high dose cytarabine, ritUXimab and thiotepa (MATRIX) therapy         | 508 |
|  |   | LEAM Autologous Transplant Conditioning Protocol  | 468 |
|  |   | Nordic Therapy  | 393 |
|  |   | R-IVAC Therapy (Patients greater than 65 years)   | 404 |
|  |   | R-IVAC Therapy (Patients less than or equal to 65 years)                                      | 399 |
|  |   | ritUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B                       | 467 |
|  |   | (R*)- ESHAP Therapy   | 394 |
|  |   | High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy                       | 666 |
|  |   | ESHAP Therapy   | 838 |
|  | Leukaemia   | FLAG Therapy  | 363 |
|  |   | Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy                                   | 682 |
| Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy |   | 683   |     |
| Transplant   | Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD | 638   |     |
| Dabrafenib   | Skin/Melanoma   | Dabrafenib Monotherapy  | 237 |
|  |   | Trametinib and Dabrafenib Therapy   | 415 |
| Dacarbazine  | Sarcoma   | Dacarbazine (1.2 g/m2) Therapy – 21 day   | 511 |
|  | Skin/Melanoma   | Dacarbazine Therapy   | 464 |
|  | Lymphoma  | ABVD Therapy  | 290 |

|   |  |   |   |     |
|---|--|---|---|-----|
| Dacomitinib   | Lung   | Dacomitinib Monotherapy   | 565   |     |
| DACTINomycin  | Gynaecology                                      | DACTINomycin Therapy  | 247   |     |
|   |  | EMA/CO Therapy  | 248   |     |
|   |  | Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy                     | 264   |     |
|   |  |   |   |     |
| Daratumumab   | Myeloma  | Daratumumab (IV), bortezomib and dexamethasone therapy  | 560   |     |
| Daratumumab   | Myeloma  | Daratumumab Monotherapy   | 426   |     |
| Daratumumab SC  | Myeloma  | Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy                                 | 609   |     |
|   |  | Daratumumab SC Monotherapy  | 604   |     |
|   |  | Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy                        | 695   |     |
|   |  |   |   |     |
|   |  | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy                 | 703   |     |
|   |  |   | 752   |     |
|   |  | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy             | 755   |     |
|   |  |   | 756   |     |
| Daunorubicin  | Leukaemia/BMT                                    | DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)   | 360   |     |
|   |  | DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)  | 359   |     |
|   |  | Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction) | 612   |     |
|   |  | Leukaemia   | Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy | 682 |
| Decitabine  | Leukaemia/BMT                                    | Decitabine Monotherapy – AML (28 day cycle)   | 231   |     |
| Degarelix   | Genitourinary                                    | Degarelix Therapy- 28 day   | 481   |     |
| Denosumab   | Breast, Genitourin                               | Denosumab 120mg Therapy   | 741   |     |
| Dinutuximab beta  | Paediatric                                       |   |   |     |
|   | Oncology   | Dinutuximab beta and Isotretinoin Therapy   | P00548  |     |
| DOCEtaxel   | Breast   | DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day   | 250   |     |
|   |  | DOCEtaxel Monotherapy 100mg/m2 – 21 day cycle   | 202   |     |
|   |  | DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle  | 203   |     |
|   |  | DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days  | 258   |     |
|   |  | DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle                        | 423   |     |
|   |  | Pertuzumab + Trastuzumab + DOCEtaxel  | 204   |     |
|   |  | DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy                             | 722   |     |
|   |  | DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy                        | 731   |     |
|   |  | DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy                     | 789   |     |
|   |  | Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle                     | 796   |     |
|   |  | Gastrointestinal  | DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle                | 203 |
|   |  |   | FLOT Therapy-14 day   | 344 |
|   |  | Genitourinary   | DOCEtaxel 75mg/m2 - Prednisolone combination therapy        | 546 |
|   |  |   | DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle                | 203 |
|   | DOCEtaxel Monotherapy 50mg/m2 Monotherapy-14 day |   | 313   |     |
|   | Gynaecology                                      | DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle  | 203   |     |
|   | Head & Neck                                      | DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy   | 324   |     |
| DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy |  | 323   |   |     |

|  |  |  |   |   |     |
|--|--|--|---|---|-----|
| DOCEtaxel  | Head & Neck  | Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery  | 315   |   |     |
|  | Lung   | DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle   | 203   |   |     |
|  |  | Nindetanib Therapy   | 372   |   |     |
|  | Sarcoma  | Gemcitabine and DOCEtaxel Therapy - 21 day   | 501   |   |     |
| DOXOrubicin  | Breast   | CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy | 348   |   |     |
|  |  | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)                                  | 278   |   |     |
|  |  | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)                                    | 485   |   |     |
|  |  | Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)                 | 316   |   |     |
|  |  | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)              | 433   |   |     |
|  |  | DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle   | 423   |   |     |
|  |  | DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day  | 252   |   |     |
|  |  | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)   | 260   |   |     |
|  |  | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)                         | 432   |   |     |
|  |  | Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)           | 745   |   |     |
|  | Gastrointestinal   | Genitourinary  | Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy | 734   |     |
|  |  |  | DOXOrubicin (60mg/m2) Therapy   | 386   |     |
|  |  |  | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy  | 333   |     |
|  |  |  | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days  | 338   |     |
|  |  |  | Head & Neck   | Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day                                | 615 |
|  |  |  |   | (MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy | 463 |
|  |  |  | Sarcoma   | DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle                   | 420 |
|  |  |  |   | DOXOrubicin (60) and Ifosfamide Therapy   | 391 |
|  |  |  |   | DOXOrubicin (75) and Ifosfamide Therapy   | 392 |
|  |  |  |   | DOXOrubicin 75mg/m2 Monotherapy   | 500 |
| Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals | 675  |  |   |   |     |
|  | 747  |  |   |   |     |
| Lymphoma   | (**riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRISline and Prednisolone (*R)-CHOP Therapy– 14 days | 409  |   |   |     |
|  | (R*)-CHOP – 21 days  | 307  |   |   |     |
|  | (R**)- miniCHOP Therapy – 21 days  | 436  |   |   |     |

|                                      |                  |  |      |
|--------------------------------------|------------------|--|------|
| DOXOrubicin                          | Lymphoma         | ABVD Therapy   | 290  |
|                                      |                  | CHOEP Therapy– 21 days   | 396  |
|                                      |                  | Dose Adjusted R-EPOCH Therapy  | 355  |
|                                      |                  | Escalated Dose BEACOPP 21 day Therapy  | 354  |
|                                      |                  | Nordic Therapy   | 393  |
|                                      |                  | Obinutuzumab and CHOP Therapy – 21 day   | 549  |
|                                      |                  | R-CODOX-M Therapy (Patients greater than 65 years)   | 403  |
|                                      |                  | R-CODOX-M Therapy (Patients less than or equal to 65 years)  | 398  |
|                                      |                  | riTUXimab-HyperCVAD Therapy (MCL) – Part A   | 466  |
|                                      |                  | Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days                  | 841  |
|                                      |                  | riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days | 667  |
|                                      |                  | Dose Adjusted R (S/C)-EPOCH Therapy  | 672  |
|                                      |                  | Brentuximab vedotin and Cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) Therapy                 | 801  |
|                                      |                  | Durvalumab   | Lung |
| Durvalumab 1500mg Monotherapy-28 Day | 655              |  |      |
| Encorafenib                          | Skin/Melanoma    | Encorafenib and Binimetinib Therapy  | 563  |
| Enfortumab vedotin                   | Genitourinary    | Enfortumab vedotin Monotherapy   | 846  |
| Entrectinib                          | Lung             | Entrectinib Therapy  | 702  |
| Enzalutamide                         | Genitourinary    | Enzalutamide Monotherapy   | 233  |
| epiRUBicin                           | Breast           | 5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy                                | 265  |
|                                      |                  | 5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy                                   | 269  |
|                                      |                  | epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day   | 263  |
|                                      |                  | epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day   | 262  |
|                                      | Gastrointestinal | epiRUBicin, CISplatin and 5-FU (ECF) Therapy   | 240  |
|                                      |                  | epiRUBicin, CISplatin and Capecitabine (ECX) Therapy   | 380  |
|                                      |                  | epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day   | 429  |
| Eribulin                             | Breast           | EriBULLin Monotherapy  | 228  |
|                                      |                  | eriBULin Monotherapy – 28 Day  | 743  |
| Erlotinib                            | Lung             | Erlotinib Monotherapy  | 219  |
| Etoposide                            | Genitourinary    | CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen                   | 453  |
|                                      |                  | TICE -Autologous Conditioning Germ Cell Tumour Regimen   | 437  |
|                                      |                  | EMA/CO Therapy   | 248  |
|                                      | Gynaecology      | PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy                           | 266  |
|                                      |                  | Two Day Etoposide CISplatin (EP) Therapy   | 267  |
|                                      |                  | Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy                            | 264  |
|                                      |                  | CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day                              | 279  |
|                                      |                  | CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day                     | 561  |
|                                      | Lung             | CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day   | 271  |
|                                      |                  | CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day                     | 456  |
|                                      |                  | CISplatin (75mg/m2) + Etoposide Therapy-21 day   | 280  |



|                |                   |   |  |     |
|----------------|-------------------|---|--|-----|
| Etoposide      | Lung              | Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy               | 689  |     |
|                |                   | CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day             | 279  |     |
|                |                   | Sarcoma   | Ifosfamide Etoposide (IE) Therapy  | 596 |
|                | Lymphoma          |   | Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals | 675 |
|                |                   |   | (R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy   | 397 |
|                |                   |   | BEAM Autologous Transplant Conditioning Protocol   | 408 |
|                |                   |   | Brentuximab vedotin and ESHAP therapy (BRESHAP)  | 530 |
|                |                   |   | CHOEP Therapy– 21 days   | 396 |
|                |                   |   | Dose Adjusted R-EPOCH Therapy  | 355 |
|                |                   |   | Escalated Dose BEACOPP 21 day Therapy  | 354 |
|                |                   |   | LEAM Autologous Transplant Conditioning Protocol   | 468 |
|                |                   |   | R-CEOP Therapy – 21 days   | 510 |
|                |                   |   | R-IVAC Therapy (Patients greater than 65 years)  | 404 |
|                |                   |   | R-IVAC Therapy (Patients less than or equal to 65 years)   | 399 |
|                |                   |   | SMILE Therapy (NK or T-cell lymphoma)  | 407 |
|                |                   |   | (R*)- ESHAP Therapy  | 394 |
|                |                   |   | Brentuximab vedotin and ICE Therapy  | 528 |
|                |                   |   | Dose Adjusted R (S/C)-EPOCH Therapy  | 672 |
|                |                   |   | ESHAP Therapy  | 838 |
|                |                   |   | ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy  | 842 |
|                | Lymphoma          | (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient | 751  |     |
|                | Genitourinary/Gyn |   | Bleomycin, Etoposide and CISplatin (BEP)Therapy  | 300 |
|                |                   |   | Etoposide and CISplatin 20mg/m2 (EP) Therapy   | 301 |
| Transplant     |                   | Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD                   | 638  |     |
| Etoposide Oral | Lung              | CARBOplatin and Oral Etoposide Therapy-21 days                                      | 319  |     |
|                |                   | Oral Etoposide Therapy  | 388  |     |
|                | Lymphoma          | R-CEOP Therapy – 21 days  | 510  |     |
| Everolimus     | Breast            | Everolimus and Exemestane Therapy   | 322  |     |
|                | Genitourinary     | Everolimus Monotherapy  | 320  |     |
|                | Neuroendocrine    | Everolimus Monotherapy  | 320  |     |
| Exemestane     | Breast            | Everolimus and Exemestane Therapy   | 322  |     |
|                |                   | Exemestane Monotherapy  | 376  |     |
| Fedratinib     | Leukaemia         | Fedratinib Therapy  | 788  |     |
| Fludarabine    | Leukaemia/BMT     | FLAG:Ida 8mg/m2 Therapy   | 362  |     |
|                |                   | Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy                       | 241  |     |
|                |                   | Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy                     | 410  |     |
|                | Leukaemia         | FLAG Therapy  | 363  |     |
|                | Lymphoma (CAR-T   |   | Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL                             | 606 |
|                |                   |   | Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)                           | 608 |
|                | Leukaemia (CAR-T  |   | Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL                        | 607 |
|                | Transplant        |   | Fludarabine/Melphalan/Alemtuzumab-RIC-SIB  | 611 |



|                  |                  |  |   |                     |
|------------------|------------------|--|---|---------------------|
| Fludarabine      | Transplant       | Fludarabine/Melphalan/Alemtuzumab-RIC-MUD  | 625   |                     |
|                  |                  | Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD   | 635   |                     |
|                  |                  | Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB  | 636   |                     |
| Folinic Acid     | Gastrointestinal | Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day                                | 446   |                     |
|                  |                  | Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days                                       | 449   |                     |
|                  |                  | FLOT Therapy-14 day  | 344   |                     |
|                  |                  | FLOX Therapy   | 486   |                     |
|                  |                  | FOLFIRI (14 days)+ Cetuximab (14 days) Therapy   | 585   |                     |
|                  |                  | FOLFIRI (14 days)+ Cetuximab (7 days) Therapy  | 328   |                     |
|                  |                  | FOLFIRI Therapy-14 day   | 227   |                     |
|                  |                  | FOLFIRINOX Therapy   | 329   |                     |
|                  |                  | FOLFOX-4 Therapy-14 day  | 210   |                     |
|                  |                  | FOLFOXIRI Therapy  | 555   |                     |
|                  |                  | Modified FOLFIRINOX Therapy  | 515   |                     |
|                  |                  | Modified FOLFOX-6 Chemoradiation Therapy-14 day  | 509   |                     |
|                  |                  | Modified FOLFOX-6 Therapy-14 day   | 209   |                     |
|                  |                  | Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen | 427   |                     |
|                  |                  | Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day  | 448   |                     |
|                  |                  | Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day                              | 447   |                     |
|                  |                  | QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly                | 428   |                     |
|                  |                  | Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen | 427   |                     |
|                  |                  | 5-Fluorouracil and Folinic Acid Therapy-14 day   | 660   |                     |
|                  |                  | FOLFIRINOX Therapy - (Rectal Carcinoma)  | 691   |                     |
|                  |                  | Cetuximab and FOLFOX-4 Therapy   | 692   |                     |
|                  |                  | Trastuzumab and FOLFOX-6 Modified Therapy-14 day                                       | 704   |                     |
|                  |                  | Cetuximab and FOLFOX-6 (modified) Therapy  | 733   |                     |
|                  |                  | Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days                                      | 783   |                     |
|                  |                  | Pembrolizumab and FOLFOX-6 Modified Therapy  | 839   |                     |
|                  |                  | Lymphoma   | R-CODOX-M Therapy (Patients greater than 65 years)  | 403                 |
|                  |                  |  | R-CODOX-M Therapy (Patients less than or equal to 65 years)                               | 398                 |
|                  |                  |  | SMILE Therapy (NK or T-cell lymphoma)   | 407                 |
|                  |                  |  | riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapy | 664                 |
|                  |                  | Fulvestrant  | Breast  | Fulvestrant Therapy |
|                  | Gefitinib        | Lung   | Gefitinib Monotherapy   | 220                 |
|                  | Gemcitabine      | Breast   | Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days                                      | 430                 |
|                  |                  |  | Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days                     | 524                 |
| Gastrointestinal |                  | Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day                        | 383   |                     |
|                  |                  | Gemcitabine (1000mg/m2) and RT therapy   | 521   |                     |
|                  |                  | Gemcitabine (1000mg/m2) Monotherapy - 28 day   | 284   |                     |
|                  |                  | Gemcitabine (1000mg/m2) Monotherapy - 56 day   | 283   |                     |
|                  |                  | Gemcitabine (400mg/m2) and RT therapy  | 522   |                     |
|                  |                  | Gemcitabine (600mg/m2) and RT therapy  | 559   |                     |
|                  |                  | Gemcitabine + Capecitabine Therapy   | 384   |                     |
|                  |                  | Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day                                    | 256   |                     |
|                  |                  | Genitourinary  | Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day                           | 310                 |

|             |                   |  |   |     |
|-------------|-------------------|--|---|-----|
| Gemcitabine | Genitourinary     | Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day  | 282   |     |
|             |                   | Gemcitabine (1000mg/m2 ) and CISplatin (35mg/m2 ) Therapy- 21 day  | 622   |     |
|             |                   | Gemcitabine (1000mg/m2 ) and CISplatin (70mg/m2 ) Therapy- 21 day  | 628   |     |
|             | Gynaecology       | Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day  | 306   |     |
|             |                   | Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day  | 499   |     |
|             | Head & Neck       | Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day   | 517   |     |
|             |                   | Gemcitabine (1250mg/m2) Monotherapy - 21 day   | 514   |     |
|             | Lung              | Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day  | 310   |     |
|             |                   | Gemcitabine (1000mg/m2) Monotherapy - 28 day   | 284   |     |
|             |                   | Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day  | 281   |     |
|             | Sarcoma           | Gemcitabine and DOCEtaxel Therapyi - 21 day  | 501   |     |
|             | Lymphoma          | R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day  | 506   |     |
|             |                   | riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)<br>(*riTUXimab)-Gemcitabine Cyclophosphamide<br>vinCRISine and PrednisolONE (*R)-GCVP) Therapy–21 days | 441<br><br>737  |     |
|             | Gemtuzumab ozogam | Leukaemia/BMT  | Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction) | 612 |
| Goserelin   | Genitourinary     | Goserelin 10.8mg-12 Weekly Therapy   | 477   |     |
|             |                   | Goserelin 3.6mg Therapy- 4 weeks   | 478   |     |
| Ibrutinib   | Lymphoma          | Ibrutinib Therapy (Mantly Cell Lymphoma)   | 297   |     |
|             | Leukaemia         | Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)  | 296   |     |
| Idarubicin  | Leukaemia/BMT     | FLAG:Ida 8mg/m2 Therapy  | 362   |     |
|             |                   | Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy   | 366   |     |
| Idelalisib  | Leukaemia/BMT     | Idelalisib and riTUXimab Therapy   | 389   |     |
|             | Lymphoma          | Idelalisib Monotherapy   | 291   |     |
| Ifosfamide  | Genitourinary     | TICE -Autologous Conditioning Germ Cell Tumour Regimen   | 437   |     |
|             |                   | Sarcoma  | DOXOrubicin (60) and Ifosfamide Therapy   | 391 |
|             |                   | DOXOrubicin (75) and Ifosfamide Therapy  | 392   |     |
|             |                   | Ifosfamide Etoposide (IE) Therapy  | 596   |     |
|             |                   | Etoposide and ifosfamide - vinCRISine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals  | 675   |     |
|             |                   | Infusional Ifosfamide Therapy  | 747   |     |
|             |                   | (R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy   | 679   |     |
|             | Lymphoma          |  | Therapy   | 397 |
|             |                   |  | R-IVAC Therapy (Patients greater than 65 years)   | 404 |
|             |                   |  | R-IVAC Therapy (Patients less than or equal to 65 years)                                      | 399 |
|             |                   |  | SMILE Therapy (NK or T-cell lymphoma)   | 407 |
|             |                   |  | Brentuximab vedotin and ICE Therapy   | 528 |
|             |                   |  | ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy   | 842 |
|             | Lymphoma          | (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient  | 751   |     |

|                          |                        |   |                                      |
|--------------------------|------------------------|---|--------------------------------------|
| Imatinib                 | Sarcoma                | Imatinib Therapy-GIST   | 335                                  |
| Inotuzumab<br>ozogamicin | Leukaemia/BMT          | Inotuzumab ozogamicin Monotherapy   | 537                                  |
| Ipilimumab               | Gastrointestinal       | Nivolumab 3mg Ipilimumab 1mg Therapy  | 551                                  |
|                          |                        | Genitourinary   | Nivolumab 3mg Ipilimumab 1mg Therapy |
|                          | Lung                   | Nivolumab 360mg and Ipilimumab 1mg/kg Therapy   | 792                                  |
|                          |                        | Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy                                 | 712                                  |
|                          |                        | Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy                                 | 713                                  |
|                          |                        | Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy                                   | 714                                  |
|                          |                        | Skin/Melanoma   | Ipilimumab Monotherapy               |
|                          |                        | Nivolumab 3mg Ipilimumab 1mg Therapy  | 551                                  |
|                          |                        | Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy  | 431                                  |
| Irinotecan               | Gastrointestinal       | Aflibercept-14 days   | 238                                  |
|                          |                        | Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days  | 449                                  |
|                          |                        | Cetuximab (14 days) and Irinotecan (14 days) Therapy                                      | 331                                  |
|                          |                        | Cetuximab (7 days) and Irinotecan (14 days) Therapy                                       | 330                                  |
|                          |                        | FOLFIRI (14 days)+ Cetuximab (14 days) Therapy  | 585                                  |
|                          |                        | FOLFIRI (14 days)+ Cetuximab (7 days) Therapy   | 328                                  |
|                          |                        | FOLFIRI Therapy-14 day  | 227                                  |
|                          |                        | FOLFIRINOX Therapy  | 329                                  |
|                          |                        | FOLFOXIRI Therapy   | 555                                  |
|                          |                        | Irinotecan Monotherapy - 21 days  | 213                                  |
|                          |                        | Modified FOLFIRINOX Therapy   | 515                                  |
|                          |                        | Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day   | 448                                  |
|                          |                        | Irinotecan 150mg/m2 Monotherapy - 28 days   | 654                                  |
|                          |                        | FOLFIRINOX Therapy - (Rectal Carcinoma)   | 691                                  |
|                          |                        | Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days   | 783                                  |
| Isotretinoin             | Paediatric<br>Oncology | Dinutuximab beta and Isotretinoin Therapy   | P00548                               |
| Ixazomib                 | Myeloma                | Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day                                 | 516                                  |
| Lapatinib                | Breast                 | Lapatinib and Capecitabine  | 217                                  |
| Larotrectinib            | Tumour Agnostic        | Larotrectinib Monotherapy - Adult   | 758                                  |
|                          |                        | Larotrectinib Monotherapy - Paediatric  | P00760                               |
| L-Asparaginase           | Lymphoma               | SMILE Therapy (NK or T-cell lymphoma)   | 407                                  |
| Lenalidomide             | Myeloma                | Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day                          | 416                                  |
|                          |                        | Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day                                 | 516                                  |
|                          |                        | Lenalidomide 25mg and Dexamethasone Therapy - 28 day                                      | 218                                  |
|                          |                        | Carfilzomib (56mg/m2 once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day   | 598                                  |
|                          |                        | Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day | 405                                  |
|                          |                        | Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day                         | 643                                  |
|                          |                        | Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy                    | 780                                  |
|                          |                        | Bortezomib and Lenalidomide RVD lite consolidation therapy                                | 781                                  |
|                          |                        | Lenalidomide RVD lite Maintenance Therapy   | 782                                  |
|                          |                        | Lenvatinib  | Gastrointestinal                     |
| Lenvatinib               | Head & Neck            | Lenvatinib -DTC Therapy   | 295                                  |
| Letrozole                | Breast                 | Letrozole Monotherapy   | 371                                  |
| Leuprorelin              | Genitourinary          | Leuprorelin 3.75mg Therapy-28 day   | 494                                  |
|                          |                        | Leuprorelin 30mg Therapy- 24 weeks  | 493                                  |

|   |   |  |     |
|---|---|--|-----|
| Leuprorelin   | Genitourinary                                       | Leuprorelin 45mg Therapy- 24 week  | 491 |
|   |   | Leuprorelin 7.5mg Therapy- 28 day  | 490 |
|   |   | Leuprorelin 11.25mg Therapy- 12 weeks  | 492 |
| Leuprorelin   | Genitourinary                                       | Leuprorelin 22.5mg Therapy- 12 weeks   | 479 |
| Lomustine   | Neuro-oncology                                      | Procarbazine Lomustine and VinCRISStine (PCV) Therapy  | 379 |
|   |   | Procarbazine, Lomustine and VinCRISStine (PCV) Therapy – 56 days   | 658 |
|   |   | Lomustine and Bevacizumab 5mg/kg Therapy   | 742 |
|   |   | Lomustine and Bevacizumab 7.5mg/kg Therapy   | 804 |
|   |   | Lomustine 130mg/m <sup>2</sup> Therapy   | 805 |
|   | CISplatin, Lomustine and vinCRISStine (CLV) Therapy | 806  |     |
|   | Lymphoma  | LEAM Autologous Transplant Conditioning Protocol   | 468 |
| Lorlatinib  | Lung  | Lorlatinib therapy   | 570 |
| Lutetium oxodotreotide  | Gastrointestinal, n                                 | Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy  | 642 |
| Melphalan   | Lymphoma  | BEAM Autologous Transplant Conditioning Protocol   | 408 |
|   |   | High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant   | 454 |
|   |   | LEAM Autologous Transplant Conditioning Protocol   | 468 |
|   | Myeloma   | Bortezomib , Melphalan and Prednisolone  | 275 |
|   |   | High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant   | 454 |
|   | Transplant  | Fludarabine/Melphalan/Alemtuzumab-RIC-SIB  | 611 |
|   |   | Fludarabine/Melphalan/Alemtuzumab-RIC-MUD  | 625 |
| Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD |   | 638  |     |
| MESNA   | Genitourinary                                       | TICE -Autologous Conditioning Germ Cell Tumour Regimen   | 437 |
|   | Lymphoma  | SMILE Therapy (NK or T-cell lymphoma)  | 407 |
|   | Lymphoma and M                                      | Cyclophosphamide 2000mg/m <sup>2</sup> For Stem Cell Mobilisation  | 438 |
| Methotrexate  | Breast  | Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy  | 381 |
|   |   | Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy  | 378 |
|   |   | Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy   | 377 |
|   | Genitourinary                                       | CISplatin, Methotrexate and Vinblastine Therapy  | 337 |
|   |   | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy  | 333 |
|   |   | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days  | 338 |
|   | Gynaecology   | EMA/CO Therapy   | 248 |
|   |   | Intrathecal Methotrexate for CNS Prophylaxis in GTN  | 249 |
|   |   | Methotrexate 8 day Charing Cross Regimen   | 246 |
|   |   | Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy  | 264 |
|   | Sarcoma   | (MAP) Methotrexate (12000mg/m <sup>2</sup> ) DOXOrubicin (37.5mg/m <sup>2</sup> /day) and CISplatin (60mg/m <sup>2</sup> ) Therapy | 463 |
|   |   | VinBLASStine and Methotrexate Therapy  | 554 |
|   | Lymphoma  | High dose Methotrexate, high dose cytarabine, riTUXImab and thiotepa (MATRix) therapy  | 508 |
|   |   | R-CODOX-M Therapy (Patients greater than 65 years)   | 403 |
|   |   | R-CODOX-M Therapy (Patients less than or equal to 65 years)  | 398 |
| riTUXImab-HyperCVAD Therapy (MCL) – Part A                        |   | 466  |     |
|   |   | SMILE Therapy (NK or T-cell lymphoma)  | 407 |

|                            |                    |   |                     |
|----------------------------|--------------------|---|---------------------|
| Methotrexate               | Lymphoma           | riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B                   | 467                 |
|                            |                    | riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapy | 664                 |
|                            | Transplant         | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor              | 629                 |
|                            |                    | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor                | 630                 |
|                            |                    | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD                                     | 631                 |
|                            |                    | Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD  | 635                 |
|                            |                    | Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB   | 636                 |
|                            |                    | Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB                                     | 637                 |
|                            |                    | Busulfan/Cyclophosphamide MAC-MUD   | 639                 |
|                            |                    | Busulfan/Cyclophosphamide MAC-SIB   | 641                 |
|                            |                    | Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor                   | 662                 |
|                            |                    | Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor                 | 663                 |
|                            | Methylprednisolone | Lymphoma  | (R*)- ESHAP Therapy |
| ESHAP Therapy              |                    |   | 838                 |
| Midostaurin                | Leukaemia          | Midostaurin Maintenance Therapy   | 661                 |
|                            |                    | Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy                               | 682                 |
|                            |                    | Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy                        | 683                 |
| Mifamurtide                | Sarcoma            | Mifamurtide   | 100                 |
| mitoMYcin                  | Gastrointestinal   | 5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy                               | 451                 |
|                            |                    | mitoMYcin and Capecitabine Chemoradiation Therapy   | 727                 |
|                            | Genitourinary      | 5-Fluorouracil and mitoMYcin Chemoradiation Therapy                                       | 450                 |
| Mogamulizumab              | Lymphoma           | Mogamulizumab Therapy   | 761                 |
| Nab-PACLitaxel             | Breast             | Atezolizumab and nab-PACLitaxel Therapy   | 688                 |
| Nab-PACLitaxel (Abraxane®) | Breast             | Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle  | 230                 |
|                            |                    |   | 736                 |
|                            | Gastrointestinal   | Nab-PACLitaxel (Abraxane®) and Gemcitabine – 28 day                                       | 256                 |
| Nindetanib                 | Lung               | Nindetanib Therapy  | 372                 |
| Niraparib                  | Gynaecology        | Niraparib Monotherapy   | 571                 |
| Niraparib/abiraterone      | Genitourinary      | Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy                      | 848                 |
| Nivolumab                  | Gastrointestinal   | Nivolumab 3mg Ipilimumab 1mg Therapy  | 551                 |
|                            |                    | Nivolumab Monotherapy 240mg-14 day  | 483                 |
|                            |                    | Nivolumab Monotherapy 480mg-28day   | 484                 |
|                            |                    | Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy                  | 816                 |
|                            |                    | Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy                  | 832                 |
|                            |                    | Nivolumab and FOLFOX-6 Modified Therapy   | 844                 |
|                            | Genitourinary      | Nivolumab 3mg Ipilimumab 1mg Therapy  | 551                 |
|                            |                    | Nivolumab Monotherapy 240mg-14 day  | 483                 |
|                            |                    | Nivolumab Monotherapy 480mg-28day   | 484                 |
|                            | Head & Neck        | Nivolumab Monotherapy 240mg-14 day  | 483                 |

|              |   |  |  |
|--------------|---|--|--|
| Nivolumab    | Head & Neck   | Nivolumab Monotherapy 480mg-28day  | 484  |
|              |   | Lung   | Nivolumab Monotherapy 240mg-14 day                 |
|              | Nivolumab Monotherapy 480mg-28day                         |  | 484  |
|              | Nivolumab 360mg and Ipilimumab 1mg/kg Therapy             |  | 792  |
|              | Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy |  | 712  |
|              | Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy |  | 713  |
|              | Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy   |  | 714  |
|              | Skin/Melanoma   |  | Nivolumab 3mg Ipilimumab 1mg Therapy               |
|              |   | Nivolumab Monotherapy 240mg-14 day   | 483  |
|              |   | Nivolumab Monotherapy 480mg-28day  | 484  |
|              |   | Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy   | 431  |
|              | Lymphoma  | Nivolumab Monotherapy 240mg-14 day   | 483  |
|              |   | Nivolumab Monotherapy 480mg-28day  | 484  |
| Obinutuzumab | Leukaemia/BMT   | Obinutuzumab and Chlorambucil Therapy  | 286  |
|              |   | Lymphoma   | Obinutuzumab and Bendamustine Therapy-28 day cycle |
|              | Obinutuzumab and CHOP Therapy – 21 day                    |  | 549  |
|              | obinutuzumab and CVP therapy -21 days                     |  | 550  |
|              | Obinutuzumab Maintenance Therapy -56 day                  | 425  |  |
| Olaparib     | Genitourinary   | Olaparib (Tablet) Monotherapy  | 588  |
|              | Gynaecology   | Olaparib (Tablet) Monotherapy  | 588  |
|              |   | Olaparib (Tablet) and Bevacizumab Therapy  | 746  |
| Osimertinib  | Lung  | Osimertinib Monotherapy  | 353  |
| Oxaliplatin  | Gastrointestinal  | Bevacizamab 5mg/kg and Modified FOLFOX-6 Therapy-14 day  | 446  |
|              |   | Capecitabine/Oxaliplatin (XELOX) Therapy   | 321  |
|              |   | epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day   | 429  |
|              |   | epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy   | 239  |
|              |   | FLOT Therapy-14 day  | 344  |
|              |   | FLOX Therapy   | 486  |
|              |   | FOLFIRINOX Therapy   | 329  |
|              |   | FOLFOX-4 Therapy-14 day  | 210  |
|              |   | FOLFOXIRI Therapy  | 555  |
|              |   | Modified FOLFIRINOX Therapy  | 515  |
|              |   | Modified FOLFOX-6 Chemoradiation Therapy-14 day  | 509  |
|              |   | Modified FOLFOX-6 Therapy-14 day   | 209  |
|              |   | Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day  | 447  |
|              |   | FOLFIRINOX Therapy - (Rectal Carcinoma)  | 691  |
|              |   | Cetuximab and FOLFOX-4 Therapy   | 692  |
|              |   | Trastuzumab and FOLFOX-6 Modified Therapy-14 day   | 704  |
|              |   | Cetuximab and FOLFOX-6 (modified) Therapy  | 733  |
|              |   | Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days  | 783  |
|              |   | Pembrolizumab and FOLFOX-6 Modified Therapy  | 839  |
|              | Nivolumab and FOLFOX-6 Modified Therapy                   | 844  |  |
| Lymphoma     | R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day   | 506  |  |
| PACLitaxel   | Breast  | CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy | 348  |
|              |   | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)                                  | 278  |
|              |   | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)                                    | 485  |
|              |   | Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)                 | 316  |



|            |               |   |  |     |
|------------|---------------|---|--|-----|
| PACLitaxel | Breast        | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)               | 433  |     |
|            |               | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)  | 260  |     |
|            |               | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)                          | 432  |     |
|            |               | PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)  | 512  |     |
|            |               | Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle   | 507  |     |
|            |               | PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day   | 226  |     |
|            |               | PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day   | 621  |     |
|            |               | Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy  | 738  |     |
|            |               | Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)            | 745  |     |
|            |               | Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)   | 775  |     |
|            |               | Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)  | 790  |     |
|            |               | Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle   | 797  |     |
|            |               | PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy  | 815  |     |
|            |               | Weekly CARBOplatin (AUC 2) and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy | 734  |     |
|            |               | Gastrointestinal  | CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks | 422 |
|            |               |   | PACLitaxel Monotherapy 80mg/m2 7day  | 226 |
|            |               |   | PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day                                      | 621 |
|            | Genitourinary | TICE -Autologous Conditioning Germ Cell Tumour Regimen  | 437  |     |
|            |               | PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day   | 226  |     |
|            |               | PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day   | 621  |     |
|            | Gynaecology   | CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy   | 308  |     |
|            |               | CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy  | 303  |     |
|            |               | PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy  | 266  |     |
|            |               | PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day   | 226  |     |
|            |               | Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy  | 620  |     |
|            |               | PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day   | 621  |     |
|            |               | CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer                                   | 676  |     |
|            |               | Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2  | 716  |     |
|            |               | Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy  | 766  |     |
|            |               | Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy  | 769  |     |



|                                 |                  |   |     |
|---------------------------------|------------------|---|-----|
| PACLitaxel                      | Gynaecology      | Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy        | 799 |
|                                 |                  | Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy | 811 |
|                                 |                  | Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy              | 817 |
|                                 | Lung             | CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy                            | 304 |
|                                 |                  | Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy                     | 579 |
|                                 |                  | Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy                          | 309 |
|                                 |                  | PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day                   | 226 |
|                                 |                  | PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day                         | 621 |
|                                 |                  | Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy                     | 712 |
|                                 |                  |   |     |
| Palbociclib                     | Breast           | Palbociclib Therapy-28 day  | 414 |
| Panitumumab                     | Gastrointestinal | Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day                               | 448 |
|                                 |                  | Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day                     | 447 |
|                                 |                  | Panitumumab 6mg/kg Therapy  | 225 |
| Pazopanib                       | Genitourinary    | Pazopanib Therapy   | 445 |
|                                 | Sarcoma          | Pazopanib Therapy   | 445 |
| Pegylated Liposoma              | Gynaecology      | Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy                  | 375 |
|                                 |                  | Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day  | 624 |
|                                 |                  | Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy                 | 772 |
|                                 | Sarcoma          | Pegylated Liposomal DOXOrubicin 20mg/m2 21 days                               | 462 |
| Pegylated Liposoma              | Breast           | Pegylated Liposomal DOXOrubicin 50mg/m2 28 days                               | 205 |
|                                 | Gynaecology      | Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day  | 624 |
|                                 |                  | Pegylated Liposomal DOXOrubicin 50mg/m2 28 days                               | 205 |
|                                 | Sarcoma          | Pegylated Liposomal DOXOrubicin 50mg/m2 28 days                               | 205 |
| Pembrolizumab                   | Gastrointestinal | Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy  | 739 |
|                                 |                  | Pembrolizumab and FOLFOX-6 Modified Therapy                                   | 839 |
|                                 | Genitourinary    | Pembrolizumab 200mg Monotherapy   | 455 |
|                                 |                  | Pembrolizumab 400mg Monotherapy   | 558 |
|                                 |                  | Pembrolizumab 200mg and Axitinib Therapy                                      | 583 |
|                                 | Gynaecology      | Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy | 811 |
|                                 |                  | Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy              | 817 |
|                                 |                  |   |     |
|                                 | Head & Neck      | Pembrolizumab 400mg Monotherapy   | 558 |
|                                 |                  |   |     |
|                                 | Lung             | Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy                 | 705 |
|                                 |                  | Pembrolizumab, CISplatin and 5-Fluorouracil Therapy                           | 706 |
|                                 |                  | Pembrolizumab 200mg Monotherapy   | 455 |
|                                 |                  | Pembrolizumab 400mg Monotherapy   | 558 |
|                                 |                  | Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy                     | 579 |
|                                 |                  | Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy                     | 568 |
|                                 |                  | Pembrolizumab, PEMEtrexed and CISplatin Therapy                               | 569 |
|                                 | Skin/Melanoma    | Pembrolizumab 200mg Monotherapy   | 455 |
|                                 |                  | Pembrolizumab 400mg Monotherapy   | 558 |
|                                 | Lymphoma         | Pembrolizumab 200mg Monotherapy   | 455 |
| Pembrolizumab 400mg Monotherapy |                  | 558   |     |

|                        |                     |  |                   |                              |     |
|------------------------|---------------------|--|-------------------|------------------------------|-----|
| Pembrolizumab          | Paediatric Oncology | Pembrolizumab Paediatric Monotherapy   | P00711            |                              |     |
|                        | Head and Neck       | Pembrolizumab 200mg Monotherapy  | 455               |                              |     |
| PEMEtrexed             | Lung                | Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy  | 568               |                              |     |
|                        |                     | Pembrolizumab, PEMEtrexed and CISplatin Therapy  | 569               |                              |     |
|                        |                     | PEMEtrexed and CARBOplatin Therapy   | 318               |                              |     |
|                        |                     | PEMEtrexed and CISplatin Therapy   | 317               |                              |     |
|                        |                     | PEMEtrexed Monotherapy   | 222               |                              |     |
|                        |                     | Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy  | 713               |                              |     |
|                        |                     | Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy  | 714               |                              |     |
| Pertuzumab             | Breast              | Pertuzumab + Trastuzumab + DOCEtaxel   | 204               |                              |     |
|                        |                     | pertuzumab and trastuzumab and chemotherapy -21 day cycles   | 350               |                              |     |
|                        |                     | Pertuzumab Trastuzumab and VinORELBine   | 526               |                              |     |
|                        |                     | Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle  | 507               |                              |     |
|                        |                     | Pertuzumab and Trastuzumab Therapy   | 726               |                              |     |
|                        |                     | DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy  | 722               |                              |     |
|                        |                     | DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy   | 731               |                              |     |
|                        |                     | Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)  | 775               |                              |     |
|                        |                     | Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy   | 785               |                              |     |
|                        |                     | DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy  | 789               |                              |     |
| Pertuzumab/Trastuzumab | Breast              | Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)   | 790               |                              |     |
|                        |                     | Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle  | 796               |                              |     |
|                        |                     | Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle  | 797               |                              |     |
|                        |                     | Pertuzumab Trastuzumab (Phesgo®) and vinORELbine   | 798               |                              |     |
|                        |                     | Pixantrone   | Lymphoma          | Pixantrone Therapy           | 255 |
|                        |                     | Plerixafor   | Lymphoma, Myeloma | Plerixafor and G-CSF Therapy | 536 |
| Polatuzumab vedotin    | Lymphoma            | Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy  | 685               |                              |     |
| Pomalidomide           | Myeloma             | Pomalidomide and Dexamethasone   | 245               |                              |     |
| Pomalidomide           | Myeloma             | Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy   | 601               |                              |     |
| Ponatinib              | Leukaemia/BMT       | Ponatinib Therapy  | 302               |                              |     |
| prednisoLONE           | Genitourinary       | Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy   | 848               |                              |     |
| Procarbazine           | Neuro-oncology      | Procarbazine Lomustine and VinCRISTine (PCV) Therapy   | 379               |                              |     |
|                        |                     | Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days  | 658               |                              |     |
|                        | Lymphoma            | Escalated Dose BEACOPP 21 day Therapy<br>riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapy | 354<br>664        |                              |     |
| Radium 223             | Genitourinary       | Radium 223 Therapy   | 257               |                              |     |
| Regorafenib            | Gastrointestinal    | Regorafenib Monotherapy  | 244               |                              |     |
| Relugolix              | Genitourinary       | Relugolix Therapy  | 830               |                              |     |
| Ribociclib             | Breast              | Ribociclib Therapy-28 day  | 525               |                              |     |
| riTUXimab              | Leukaemia/BMT       | Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy  | 241               |                              |     |
|                        |                     | Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy  | 410               |                              |     |

|           |               |  |   |     |
|-----------|---------------|--|---|-----|
| riTUXimab | Leukaemia/BMT | Idelalisib and riTUXimab Therapy   | 389   |     |
|           |               | Venetoclax and Rituximab therapy   | 575   |     |
|           | Lymphoma      | (**riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days | 409   |     |
|           |               | (*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days               | 293   |     |
|           |               | (R*)-CHOP – 21 days  | 307   |     |
|           |               | (R**)- miniCHOP Therapy – 21 days  | 436   |     |
|           |               | (R**)-DHAP Therapy   | 395   |     |
|           |               | (R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy                               | 397   |     |
|           |               | Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy   | 532   |     |
|           |               | Dose Adjusted R-EPOCH Therapy  | 355   |     |
|           |               | High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy                | 508   |     |
|           |               | Nordic Therapy   | 393   |     |
|           |               | R-CEOP Therapy – 21 days   | 510   |     |
|           |               | R-CODOX-M Therapy (Patients greater than 65 years)   | 403   |     |
|           |               | R-CODOX-M Therapy (Patients less than or equal to 65 years)  | 398   |     |
|           |               | R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day  | 506   |     |
|           |               | riTUXimab 375 mg/m2 Combination Therapy-21 day   | 542   |     |
|           |               | RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day  | 543   |     |
|           |               | RiTUXimab 375 mg/m2 Maintenance Therapy-84 day   | 540   |     |
|           |               | RiTUXimab 375 mg/m2 Therapy-7 day  | 541   |     |
|           |               | riTUXimab and Bendamustine Therapy   | 345   |     |
|           |               | riTUXimab-HyperCVAD Therapy (MCL) – Part A   | 466   |     |
|           |               | R-IVAC Therapy (Patients greater than 65 years)  | 404   |     |
|           |               | R-IVAC Therapy (Patients less than or equal to 65 years)   | 399   |     |
|           |               | riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B                              | 467   |     |
|           |               | (R*)- ESHAP Therapy  | 394   |     |
|           |               | riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)                                      | 441   |     |
|           |               | RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day  | 599   |     |
|           |               | RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day  | 600   |     |
|           |               | riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi           | 664   |     |
|           |               | riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days | 667   |     |
|           |               | Dose Adjusted R (S/C)-EPOCH Therapy  | 672   |     |
|           |               | Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy  | 685   |     |
|           |               | (*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISTine and PrednisoLONE (*R)-GCVP) Therapy–21 days    | 737   |     |
|           |               | Leukaemia/BMT, L   | Cladribine 5 day and riTUXimab Therapy  | 531 |
|           |               |  | Cladribine Weekly and riTUXimab Therapy   | 534 |
|           |               | Lymphoma   | (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient | 751 |
|           |               |  |   |     |
|           | Ruxolitinib   | Leukaemia/BMT  | Ruxolitinib Monotherapy   | 229 |
|           | Siltuximab    | Lymphoma   | Siltuximab Monotherapy  | 277 |
|           | Sorafenib     | Gastrointestinal   | Sorafenib Therapy   | 294 |

|                                  |                  |  |     |
|----------------------------------|------------------|--|-----|
| Sorafenib                        | Genitourinary    | Sorafenib Therapy  | 294 |
|                                  | Head & Neck      | Sorafenib Therapy  | 294 |
| Sunitinib                        | Genitourinary    | SUNitinib 50mg Therapy (21 days)   | 719 |
|                                  | Sarcoma          | SUNitinib 50mg Therapy (21 days)   | 719 |
| Sunitinib                        | Genitourinary    | Sunitinib 50mg Therapy   | 325 |
|                                  | Sarcoma          | Sunitnib 50mg Therapy  | 325 |
|                                  | Neuroendocrine   | Sunitnib 37.5mg Therapy  | 327 |
| Talazoparib                      | Breast           | Talazoparib Therapy  | 605 |
| Tamoxifen                        | Breast           | Tamoxifen Monotherapy  | 253 |
| Temozolomide                     | Gastrointestinal | Capecitabine and Temozolomide Therapy*   | 505 |
|                                  | Neuro-oncology   | Temozolomide Recurrent Therapy   | 342 |
|                                  |                  | Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years   | 461 |
|                                  |                  | Temozolomide with RT and Adjuvant Therapy  | 334 |
| Temsirolimus                     | Genitourinary    | Temsirolimus Monotherapy   | 326 |
| Teysuno                          | Gastrointestinal | CISplatin and Teysuno-28 day cycle   | 235 |
| Thalidomide                      | Myeloma          | Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy   | 274 |
|                                  |                  | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy  | 703 |
|                                  |                  |  | 752 |
|                                  |                  | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy  | 755 |
|                                  |                  |  | 756 |
| Thiotepa                         | Lymphoma         | High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy  | 508 |
| Tipracil                         | Gastrointestinal | Trifluridine and Tipiracil (Lonsurf®) Therapy  | 382 |
| Tisagenlecleucel                 | Leukaemia (CAR-T | Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL  | 686 |
|                                  | Lymphoma (CAR-T  | Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL  | 687 |
| Tivozanib                        | Genitourinary    | Tivozanib Therapy  | 564 |
| Topotecan                        | Gynaecology      | Topotecan Monotherapy-5 day  | 311 |
|                                  |                  | Topotecan Monotherapy-Weekly   | 312 |
|                                  |                  | Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy   | 771 |
|                                  | Lung             | Topotecan Monotherapy-5 day  | 311 |
|                                  |                  | Topotecan Oral Monotherapy   | 587 |
| Trabectedin                      | Gynaecology      | Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy   | 375 |
|                                  | Sarcoma          | Trabectedin Monotherapy  | 374 |
| Trametinib                       | Skin/Melanoma    | Trametinib and Dabrafenib Therapy  | 415 |
| Trastuzumab                      | Breast           | Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)  | 775 |
|                                  | Gastrointestinal | Trastuzumab and FOLFOX-6 Modified Therapy-14 day   | 704 |
| Trastuzumab                      | Breast           | PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy   | 815 |
| Trastuzumab emtar                | Breast           | Trastuzumab Emtansine (Kadcyla® ) Early Breast Cancer Therapy- 21 days   | 659 |
|                                  |                  |  |     |
| Trastuzumab Emtansine (Kadcyla®) | Breast           | Trastuzumab Emtansine (Kadcyla®) - 21 days   | 206 |
| Trastuzumab IV                   | Breast           | Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) | 316 |

|                  |                |  |     |
|------------------|----------------|--|-----|
| Trastuzumab IV   | Breast         | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)    | 433 |
|                  |                | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)               | 432 |
|                  |                | PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)   | 512 |
|                  |                | Pertuzumab + Trastuzumab + DOCEtaxel   | 204 |
|                  |                | pertuzumab and trastuzumab and chemotherapy -21 day cycles   | 350 |
|                  |                | Pertuzumab Trastuzumab and VinORELBine   | 526 |
|                  |                | Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle  | 507 |
|                  |                | Trastuzumab (IV) Monotherapy 21 days   | 200 |
|                  |                | Trastuzumab (IV) Monotherapy 7 days  | 201 |
|                  |                | Pertuzumab and Trastuzumab Therapy   | 726 |
| Trastuzumab SC   | Breast         | Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH) | 745 |
|                  |                | Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days   | 502 |
| Trastuzumab      | Breast         | Trastuzumab SC 21 days-Early Breast Cancer   | 285 |
|                  |                | Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma  | 272 |
| Trastuzumab IV   | Breast         | DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days   | 258 |
|                  |                | DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy  | 722 |
| Trastuzumab SC   | Breast         | DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy   | 731 |
|                  |                | Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy   | 357 |
| Tretinoin (ATRA) | Leukaemia/BMT  | Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy   | 356 |
|                  |                | Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy   | 366 |
|                  |                | Trifluridine and Tipiracil (Lonsurf®) Therapy  | 382 |
| Triptorelin      | Genitourinary  | Triptorelin 11.25mg Therapy- 12 weeks  | 480 |
|                  |                | Triptorelin 22.6mg Therapy- 24 weeks   | 488 |
|                  |                | Triptorelin 3mg Therapy- 28 day  | 489 |
| Vandetanib       | Head & Neck    | Vandetanib Monotherapy   | 242 |
| Vemurafenib      | Skin/Melanoma  | Cobimetinib and Vemurafenib Therapy  | 373 |
|                  |                | Vemurafenib Monotherapy  | 102 |
| Venetoclax       | Leukaemia/BMT  | Venetoclax Monotherapy   | 400 |
| Venetoxlax       | Leukaemia/BMT  | Venetoclax and Rituximab therapy   | 575 |
| Vinblastine      | Genitourinary  | CISplatin, Methotrexate and Vinblastine Therapy  | 337 |
|                  |                | Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy   | 333 |
|                  |                | Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days   | 338 |
|                  | Sarcoma        | VinBLAStine and Methotrexate Therapy   | 554 |
| VinCRISStine     | Lymphoma       | ABVD Therapy   | 290 |
|                  | Gynaecology    | EMA/CO Therapy   | 248 |
|                  | Sarcoma        | Etoposide and ifosfamide - vinCRISStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals                        | 675 |
|                  |                |  |     |
|                  | Neuro-oncology | Procarbazine Lomustine and VinCRISStine (PCV) Therapy  | 379 |

|   |                |   |  |     |
|---|----------------|---|--|-----|
| VinCRISStine                              | Neuro-oncology | Procarbazine, Lomustine and VinCRISStine (PCV) Therapy – 56 days                                      | 658  |     |
|   |                | CISplatin, Lomustine and vinCRISStine (CLV) Therapy   | 806  |     |
|   | Lymphoma       | (*riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISStine and Prednisolone (*R)-CHOP Therapy– 14 days   | 409  |     |
|   |                | (*riTUXimab), Cyclophosphamide VinCRISStine and Prednisolone (*R)-CVP) Therapy– 21 days               | 293  |     |
|   |                | (R*)-CHOP – 21 days   | 307  |     |
|   |                | (R**) - miniCHOP Therapy – 21 days  | 436  |     |
|   |                | CHOEP Therapy– 21 days  | 396  |     |
|   |                | Dose Adjusted R-EPOCH Therapy   | 355  |     |
|   |                | Escalated Dose BEACOPP 21 day Therapy   | 354  |     |
|   |                | Nordic Therapy  | 393  |     |
|   |                | Obinutuzumab and CHOP Therapy – 21 day  | 549  |     |
|   |                | obinutuzumab and CVP therapy -21 days   | 550  |     |
|   |                | R-CEOP Therapy – 21 days  | 510  |     |
|   |                | R-CODOX-M Therapy (Patients greater than 65 years)  | 403  |     |
|   |                | R-CODOX-M Therapy (Patients less than or equal to 65 years)   | 398  |     |
|   |                | riTUXimab-HyperCVAD Therapy (MCL) – Part A  | 466  |     |
|   |                | Cyclophosphamide, DOXOrubicin, vinCRISStine and prednisoLONE (CHOP) Therapy– 21 days                  | 841  |     |
|   |                | riTUXimab, Methotrexate, Procarbazine and vinCRISStine (R-MPV) – 14 Days Induction Therapyi           | 664  |     |
|   |                | riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISStine and Prednisolone (R-CHOP) Therapy– 21 Days | 667  |     |
|   |                | Dose Adjusted R (S/C)-EPOCH Therapy   | 672  |     |
|   |                | (*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISStine and PrednisolONE (*R)-GCVP) Therapy–21 days    | 737  |     |
|   | Vinorelbine    | Breast  | Pertuzumab Trastuzumab (Phesgo®) and vinORELbine | 798 |
|   |                | Lung  | CARBOplatin and vinORELbine Therapy-21 Day       | 614 |
| Vinorelbine IV                            | Breast         | Intravenous Vinorelbine Monotherapy-21day   | 232  |     |
|   |                | Pertuzumab Trastuzumab and VinORELbine  | 526  |     |
|   | Gynaecology    | Intravenous Vinorelbine Monotherapy-21day   | 232  |     |
|   | Lung           | Intravenous Vinorelbine Monotherapy-21day   | 232  |     |
| Vinorelbine and CISplatin Therapy-21 days |                | 339   |  |     |
| Vinorelbine and CISplatin Therapy-28 days |                | 343   |  |     |
| Vinorelbine Oral                          | Breast         | Oral Vinorelbine Monotherapy-7days  | 259  |     |
|   | Lung           | Oral Vinorelbine Monotherapy-7days  | 259  |     |
| Vismodegib                                | Skin/Melanoma  | Vismodegib Monotherapy  | 236  |     |
| Vyxeos liposomal® (                       | Leukaemia/BMT  | Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction Therapy                                     | 613  |     |
|   |                | Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation Therapy                                 | 618  |     |
| Zanubrutinib                              | Lymphoma       | Zanubrutinib Therapy  | 708  |     |
| Zoledronic acid                           | Breast         | Zoledronic acid monotherapy   | 545  |     |
|   |                | Breast, Genitourin  | Zoledronic Acid Therapy-28 days                  | 723 |
|   |                | Zoledronic Acid Therapy-3 monthly   | 724  |     |
|   |                | Zoledronic Acid Therapy-6 monthly   | 725  |     |